UBE2S and prostate carcinoma: Specifically, immunohistochemical staining was conducted to assess UBE2S expression levels in 14 different types of tumors, including glioma, thymic adenocarcinoma, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, testicular cancer, prostate cancer, urothelial cancer, kidney cancer, pancreatic cancer, and liver cancer.